CAS
ONCT

Coppell Advisory Solutions’s Oncternal Therapeutics, Inc. Common Stock ONCT Stock Holding History

Coppell Advisory Solutions’s Portfolio ONCT Stock Details ONCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q4 		$11 Sell
1
-2
-67% -$14 ﹤0.01% 1710
2023
Q3 		$58 Buy
3
+1
+50% +$7 ﹤0.01% 1165
2023
Q2 		$13 Buy
+2
New +$13 ﹤0.01% 1428
2023
Q1 		– Sell
-3
Closed -$58 – 1168
2022
Q4 		$58 Buy
+3
New +$60 ﹤0.01% 1165

Other funds holding ONCT

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPW
Pasadena Private Wealth Pasadena, California $723M AUM 18.72% 1-Year Est. Return
RB
Richmond Brothers Jackson, Michigan $150M AUM 14.02% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
IC
IEQ Capital Foster City, California $21.5B AUM 75.26% 1-Year Est. Return

Coppell Advisory Solutions's ONCT Position: Q4 2023 in Review

Coppell Advisory Solutions reduced its Oncternal Therapeutics, Inc. Common Stock (ONCT) stake by 67% in Q4 2023, selling an estimated $14 and leaving 1 share worth $11. The position accounts for ﹤0.01% of the portfolio, ranked #1710.

Coppell Advisory Solutions first reported a position in ONCT in Q4 2022 and has held it in 4 quarters since. The position peaked at $58 in Q3 2023. 38 funds tracked by Wall St. Rank hold ONCT as of Q4 2023.

  • Coppell Advisory Solutions held 1 share of Oncternal Therapeutics, Inc. Common Stock worth $11 as of Q4 2023.
  • Coppell Advisory Solutions sold 2 Oncternal Therapeutics, Inc. Common Stock shares in Q4 2023, an estimated $14.
  • Oncternal Therapeutics, Inc. Common Stock made up ﹤0.01% of Coppell Advisory Solutions's portfolio in Q4 2023, its #1710 holding.
  • Coppell Advisory Solutions first reported a position in Oncternal Therapeutics, Inc. Common Stock in Q4 2022 and has held it in 4 quarters since.
  • Coppell Advisory Solutions's Oncternal Therapeutics, Inc. Common Stock position peaked at $58 in Q3 2023.
  • 38 funds tracked by Wall St. Rank held Oncternal Therapeutics, Inc. Common Stock as of Q4 2023.

Based on Coppell Advisory Solutions's 13F filing for Q4 2023, filed 14 Feb 2024.